Several studies have corroborated that clarithromycin, a macrolide antibiotic, has antinflammatory effects in respiratory diseases. The formulation and characterisation of a clarithromycin pressurised metered dose inhaler (pMDI) solutions was investigated. The novel solution pMDI had suitable aerosol properties for lung delivery. It demonstrated to be non toxic at the administered doses and had in vitro inhibitory effects on mucus secretion of Calu-3 cells.
The formulation of a novel macrolide solution pressurised metered dose inhaler: the use of Clarithromycin as an anti-inflammatory for bronchiectasis therapy
SAADAT VARNOUSFADERANI, Alessandro;COLOMBO, Gaia;TRAINI, DANIELA
2013
Abstract
Several studies have corroborated that clarithromycin, a macrolide antibiotic, has antinflammatory effects in respiratory diseases. The formulation and characterisation of a clarithromycin pressurised metered dose inhaler (pMDI) solutions was investigated. The novel solution pMDI had suitable aerosol properties for lung delivery. It demonstrated to be non toxic at the administered doses and had in vitro inhibitory effects on mucus secretion of Calu-3 cells.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
